tbuckley/cabot-search huggingface dataset:
Fever: Basic Mechanisms and Management
Authors: Moses Grossman
Journal: JAMA (1992)

This new book on fever was edited by Philip Mackowiak, chief of the medical service at the Veterans Administration Hospital in Baltimore. Dr Mackowiak has written three chapters himself—on drug fever, on the effects of pathogenic organisms (mostly bacteria), and on the influence of fever on pharmacokinetics and pharmacodynamics. All three chapters have appeared elsewhere as reviews. They have been somewhat expanded and reedited, and may have served as a stimulus for this book. The first few chapters are clearly written, scholarly reviews dealing with basic mechanisms of fever. Charles Dinarello's chapter on endogenous pyrogens starts with a historical overview and brings the reader right up to date with newer knowledge about the role of cytokines. The chapter is supported by 188 excellent references. Other chapters in this section cover thermoregulation, exogenous pyrogens, and prostaglandins. Further on there is another excellent chapter on antipyretics written by Wesley Clark. It has
High-quality assembly of Dermatophagoides pteronyssinus genome and transcriptome reveals a wide range of novel allergens
Authors: Angel Tsz-Yau Wan, Xiao-Yu Liu, Kevin Yi Yang, Mingqiang Wang, Jamie Sui-Lam Kwok, Xi Zeng, Zhiyuan Yang, Xiao-Jun Xiao, Carol Po-Ying Lau, Ying Li, Zhi-ming Huang, Jin-ge Ba, Aldrin Kay-Yuen Yim, Chun-Yan Ouyang, Sai-Ming Ngai, Ting-Fung Chan, Elaine Lai-Han Leung, Liang Liu, Zhi-Gang Liu, Stephen Kwok-Wing Tsui
Journal: Journal of Allergy and Clinical Immunology (2018)
Chlamydia trachomatis and cervical neoplasia
Authors: J. Schachter
Journal: JAMA (1982)

We tested 383 women with and 500 women without cervical neoplasia for antibodies against<i>Chlamydia trachomatis</i>or herpes simplex virus (HSV). Exposure to both agents was related to sexual activity, with the highest prevalence of antibodies found in women with more sex partners and who had first coitus at an earlier age. When subjects were matched for several risk factors (age, race, marital status, parity, number of sex partners, and history of venereal disease), a significant excess of antibodies against<i>C trachomatis</i>was found in cases as compared with control subjects (76.5%<i>v</i>58.4%, respectively; n=149). Because matched-pair analysis lost a substantial proportion of women with neoplasia (largely because they were older), linear logistic analysis was performed. This also showed an excess of antichlamydial antibody in cases, with an estimated odds ratio of approximately 2 for the association of antichlamydial antibody and the risk of being a case. Neither analysis found an excess of antibodies to HSV type 2 in cases. (<i>JAMA</i>1982;248:2134-2138)
Creatine kinase BB: A response marker in liver and other organs
Authors: S Malnick
Journal: Hepatology (1994)

We were interested to see the recent paper by Vauboudolle et al. (11, which adds the liver to the growing list of organs in which creatine kinase-BB (CK-BB) has proved a useful response marker.CK-BB is the major component of the estrogeninduced protein in the rat uterus (2).The immature rat uterus responds to estrogen administration by increased synthesis of mRNA for CK-BB within 30 min (3).The response to estrogen is present within the entire female reproductive tract (4).CK-BB activity also increases in response to a variety of hormones and growth factors.These include estrogens (2-41, vitamin D metabolites, steroid hormones, parathyroid hormone, human growth hormone, prolactin luteinizing hormon+releasing hormone prostaglandm E, and dibutyryl CAMP (5).In the rat, growth hormone and glucocorticoids have been shown to have an additive effect that increases CK-BB activity in the liver (6).In addition, both rat hdney stimulated to undergo hypertrophy by unilateral nephrectomy and rat liver after partial hepatectomy show an increase in CK-BB activity (Somjen D, et al., Unpublished results, 1989).Vaubourdolle et al. ( 1) have shown that CK-BB is released from damaged sinusoidal cells after an ischemic insult.It would be very interesting to examine CK-BB activity in serum and in the liver for a longer period than 30 min after reperfusion.One might expect a subsequent increase in CK-BB activity.Interestingly, an increase in CK-BB activity has been shown in fetal rat kidney and cerebellum after ischemia (7).It is proposed that the CK response could serve as a metabolic marker €or ischemia, representing part of a compensatory mechanism to overcome the energetic gap after an ischemic insult.Furthermore, it is possible to examine noninvasively by magnetic resonance spectroscopy changes in the concentration of creatine phosphate and ATP, which reflect the CK activity (8).In summary, CK-BB may be stimulated by any agent or situation involving modulation of energy regeneration.We believe that CK-BB may serve as a response marker in liver as it already does for brain (9).
Indices of Potential Lead Hazard
Authors: Herbert S. Posner
Journal: Environmental Health Perspectives (1977)

This review is concerned with the concentrations of lead in human whole blood, erythrocytes, plasma, serum, soft tissues, bone, and urine. The extent to which redistribution of some of the bound lead occurs is outlines. The effects of lead on enzyme activities and on the accumulation of metabolic intermediates in the blood and urine are described. A brief section deals with the range of signs and symptoms that can occur and differences seen between symptomatic children and adults.
Sertraline for Treatment of Depression in Acute Coronary SyndromesCounting Deaths Due to Medical ErrorsVirologic Outcomes of Complex Drug Regimens for Human Immunodeficiency VirusAllocation Concealment in Clinical Trials
Authors: François Lespérance, Nancy Frasure-Smith
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Achievement of Dietary Goals—Kansas, 1993
Journal: JAMA (1995)

Fat intake and other dietary factors are associated with increased risk for important chronic diseases, including cardiovascular disease and cancer (1-4). To characterize the nutritional behaviors of residents of Kansas, the Kansas Department of Health and Environment (KDHE) conducted a nutrition assessment survey in 1993 and has used the results as a baseline for monitoring progress toward attaining Healthy Kansans 2000 (HK2000) nutrition objectives. This report summarizes selected findings from the nutrition survey relative to three HK2000 objectives: 1) increase to 35% the proportion of adults who consume five or more daily servings of fruits and vegetables; 2) increase to 40% the proportion of adults whose dietary fat intake constitutes < 30% of their total food-energy intake (a lower fat diet); and 3) increase to 70% the proportion of adults who consume > or = 600 mg of calcium daily (75% of the Recommended Dietary Allowance for adults aged > or = 25 years [5]).
New Names
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Biochemical Journal, London
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ANOTHER WORD REGARDING CREATINURIA
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Human Epidemiology: A Review of Fiber Type and Characteristics in the Development of Malignant and Nonmalignant Disease
Authors: James A. Merchant
Journal: Environmental Health Perspectives (1990)

Consideration of the human epidemiology of diseases arising from exposure to naturally occurring and man-made mineral fibers encompasses the several forms of asbestos (chrysotile, crocidolite, amosite, anthophyllite, tremolite-actinolite), other naturally occurring silicates (talc, sepiolite, erionite, attapulgite, vermiculite, and wollastonite), and man-made mineral fibers (glass continuous filament, glass/rock/slag insulation wools, ceramic and other refractory fibers, and glass microfibers). The diseases arising from exposures to some of these fibers include pleural thickening (plaques, diffuse pleural thickening, and calcification), pulmonary fibrosis, lung cancers, mesothelioma of the pleura and peritoneum, and other cancers). Risk factors important in assessing these diseases include assessment of latency, duration of exposure, cumulative exposure, fiber origin and characteristics (length and diameter), other possible confounding occupational or environmental exposures, and smoking. Methodological issues commonly presenting problems in evaluation of these data include assessment of the adequacy of environmental exposures, particularly in regard to fiber identification, distribution, and concentration over the duration of exposure, and the adequacy of study design to detect health effects (disease frequency, latency, and cohort size). Research priorities include further assessment and standardization of pleural thickening relative to fiber exposure, uniform mesothelioma surveillance, further epidemiological assessment of certain silicate and man-made mineral fiber cohorts with emphasis given to assessment of tremolite and small diameter glass and ceramic fibers. Further assessment of possible health risks of the general public should await improved definition of relevant fiber exposure in ambient air.
Anticoagulants
Authors: Douglas S. Riggs
Journal: New England Journal of Medicine (1950)

WHEN a blood vessel has been severed the prompt coagulation of blood is an essential safeguard against fatal hemorrhage. Yet the same defense mechanism may itself threaten life through the formation and propagation of an intravascular clot. Although heparin had been employed successfully as early as 1935 to prevent intravascular clotting, its brief duration of action and high cost discouraged general use. The discovery of Dicumarol stimulated enormous interest in the anticoagulant drugs and the ability of these agents to prevent thrombosis and embolism has now been established beyond doubt. It is equally well established that the careless administration of . . .
Notes on Books
Journal: BMJ (1876)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Notes on Books Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Relief of cancer pain by surgical and nerve blocking procedures
Authors: D. M. Long
Journal: JAMA (1980)

WHILE virtually any cancer is capable of causing pain, those that most frequently require pain therapy are the invasive head and neck cancers, carcinoma of the lung, carcinoma of the breast, carcinoma of the pancreas, colorectal cancer, and carcinoma of the cervix. When making a decision about cancer pain therapy, it is important to recognize the phase of the disease, estimate the patient's longevity, and make an accurate diagnosis concerning the cause of the pain. The aphorism that pain in a cancer patient is due to the tumor until proved otherwise is undoubtedly true, but other causes of pain do exist and must be carefully separated from the pain of the cancer itself, for the therapies may be extremely different. As a general rule, destructive procedures should not be used in the early phases of cancer pain, for the primary therapy offers the best chance of pain relief. During an
CREDIT FOR DISCOVERY
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Efficacy of Duloxetine on Cognition, Depression, and Pain in Elderly Patients With Major Depressive Disorder: An 8-Week, Double-Blind, Placebo-Controlled Trial
Authors: Joel Raskin
Journal: American Journal of Psychiatry (2007)

Objective: This study compared the effects of duloxetine, 60 mg/day, versus placebo on cognition, depression, and pain in elderly patients with recurrent major depressive disorder. Method: Patients were randomly assigned (2:1) to duloxetine, 60 mg/day (N=207), or placebo (N=104) for 8 weeks in a double-blind study. The primary outcome measure was a prespecified composite cognitive score composed of four individual tests. Secondary measures included the Geriatric Depression Scale, the Hamilton Depression Rating Scale, the Visual Analogue Scale assessing pain, and standard safety and tolerability assessments. Results: Patients had a median age of 72 years (range=65–90). Duloxetine demonstrated significantly greater improvement in the composite cognitive score versus placebo (least-squares mean change from baseline to endpoint: 1.95 versus 0.76), driven by improved verbal learning and memory. Duloxetine treatment showed significantly greater baseline-to-endpoint reductions in both Hamilton depression scale (–6.49 versus –3.72) and Geriatric Depression Scale (–4.07 versus –1.34) total scores compared with placebo. Hamilton depression scale response (37.3% versus 18.6%) and remission (27.4% versus 14.7%) rates at endpoint were significantly higher for duloxetine than for placebo. Duloxetine significantly improved Visual Analogue Scale scores for back pain and time in pain while awake versus placebo. Significantly fewer patients receiving duloxetine withdrew from the study because of lack of efficacy (2.9% versus 9.6%); the incidences of discontinuation due to adverse events were similar for duloxetine and placebo (9.7% versus 8.7%). Conclusions: Duloxetine improved cognition, depression, and some pain measures and was safe and well tolerated in elderly patients with recurrent major depressive disorder.
Is your patient fit? A simple supplementary test for evaluating a patient's fitness
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Serum levels of fluconazole in patients after cytotoxic chemotherapy for hematological malignancy
Authors: Masahiro Kami, Yasufusa Sawada, Shin‐ichiro Mori, Junji Hirate, Nakao Kojima, Yoshinobu Kanda, Akiko Moriya, Koichiro Yuji, Toshiki Saito, Shigeru Chiba, Hisamaru Hirai
Journal: American Journal of Hematology (2001)
High altitude illness
Authors: Charles S. Houston
Journal: JAMA (1977)

<h3>In Reply.—</h3> Dr Smith is correct: children are more than ten times as susceptible to high altitude pulmonary edema as are adults.<sup>1</sup>Physical exertion does seem to increase susceptibility and worsen symptoms,<sup>1</sup>but it is not advisable for victims or susceptible individuals to sink into somnolent bed rest; mild activity is better. Dr Smith's observations of the value of acetazolamide are borne out by others—for example, the incidence of serious altitude sickness among the 3,500 climbers (out of 8,000 starters) who get above 4,800 m each year on Mt Kenya since use of this drug has become widespread (P. Snyder, personal communication). Double-blind studies are almost impossible: acetazolamide makes beer taste awful and causes paresthesias in extremities and around the mouth that are not due to hypocapnia. Two tablets for three days before and two days after ascent is recommended. Whether or not risk is increased if the
A Randomized Controlled Clinical Trial of Psychoanalytic Psychotherapy for Panic Disorder
Authors: Barbara Milrod
Journal: American Journal of Psychiatry (2007)

Objective: The purpose of this study was to determine the efficacy of panic-focused psychodynamic psychotherapy relative to applied relaxation training, a credible psychotherapy comparison condition. Des- pite the widespread clinical use of psychodynamic psychotherapies, randomized controlled clinical trials evaluating such psychotherapies for axis I disorders have lagged. To the authors’ knowledge, this is the first efficacy randomized controlled clinical trial of panic-focused psychodynamic psychotherapy, a manualized psychoanalytical psychotherapy for patients with DSM-IV panic disorder. Method: This was a randomized controlled clinical trial of subjects with primary DSM-IV panic disorder. Participants were recruited over 5 years in the New York City metropolitan area. Subjects were 49 adults ages 18–55 with primary DSM-IV panic disorder. All subjects received assigned treatment, panic-focused psychodynamic psychotherapy or applied relaxation training in twice-weekly sessions for 12 weeks. The Panic Disorder Severity Scale, rated by blinded independent evaluators, was the primary outcome measure. Results: Subjects in panic-focused psychodynamic psychotherapy had significantly greater reduction in severity of panic symptoms. Furthermore, those receiving panic-focused psychodynamic psychotherapy were significantly more likely to respond at treatment termination (73% versus 39%), using the Multicenter Panic Disorder Study response criteria. The secondary outcome, change in psychosocial functioning, mirrored these results. Conclusions: Despite the small cohort size of this trial, it has demonstrated preliminary efficacy of panic-focused psychodynamic psychotherapy for panic disorder.